- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04919512
En undersøgelse af TAR-200 i kombination med Cetrelimab og Cetrelimab alene hos deltagere med muskelinvasivt urinrørscarcinom i blæren (SunRISe-4)
En fase 2, open-label, multicenter, randomiseret undersøgelse af TAR-200 i kombination med Cetrelimab og Cetrelimab alene hos deltagere med muskelinvasivt urinrørscarcinom i blæren, som er planlagt til radikal cystektomi og ikke er berettigede til eller nægter platin- Baseret neoadjuverende kemoterapi
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop distant metastases. The TAR-200/ gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine minitablets and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The standard of care in MIBC includes radical cystectomy (RC) with urinary diversion and is considered the preferred treatment option for participants who are considered surgical candidates. Study consists of a Screening phase, Treatment phase and follow-up phase. The total duration of study will be up to 2 years and 6 months. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during this study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Udvidet adgang
Kontakter og lokationer
Studiesteder
-
-
-
Brugge (Bruges), Belgien, 8000
- AZ Sint Jan Brugge Oostende AV
-
Brugge (Bruges), Belgien, 8310
- Algemeen Ziekenhuis Sint-Jan
-
Genk, Belgien, 3600
- Ziekenhuis Oost-Limburg
-
Haine-Saint-Pierre, Belgien, 7100
- Hopital de Jolimont
-
Merksem, Belgien, 2170
- ZNA Jan Palfijn
-
Mons, Belgien, 7000
- Centre Interuniversitaire Ambroise Pare - Ambroise Paré
-
-
-
-
-
London, Det Forenede Kongerige, EC1A 7BE
- Barts Health NHS Trust
-
Preston, Det Forenede Kongerige, PR2 9HT
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85741
- Urological Associates of Southern Arizona, P.C.
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Arkansas Urology
-
Little Rock, Arkansas, Forenede Stater, 72205
- UAMS Winthrop P. Rockefeller Cancer Institute
-
-
California
-
Duarte, California, Forenede Stater, 91010
- City of Hope
-
San Diego, California, Forenede Stater, 92123
- Genesis Research
-
-
Colorado
-
Golden, Colorado, Forenede Stater, 80401
- Colorodo Urology- St. Anthony Hospital
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Mayo Clinic
-
Jacksonville, Florida, Forenede Stater, 32209
- University of Florida Health Jacksonville
-
Miami, Florida, Forenede Stater, 33176
- Baptist Hospital of Miami
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Winship Cancer Institute Emory University
-
-
Illinois
-
Astoria, Illinois, Forenede Stater, 11102
- Mount Sinai Queens Infusion Center
-
Lisle, Illinois, Forenede Stater, 60532
- DuPage Medical Group
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46260
- Urology of Indiana
-
Jeffersonville, Indiana, Forenede Stater, 47130
- First Urology
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21218
- Penn Medicine - PerelmanCenter for Advanced Medicine
-
Baltimore, Maryland, Forenede Stater, 21201
- University Of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Troy, Michigan, Forenede Stater, 48084
- Michigan Institute of Urology, PC
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University Of Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic 1
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65201
- Ellis Fischel Cancer Center
-
St Louis, Missouri, Forenede Stater, 63141
- David C. Pratt Cancer Center
-
St Louis, Missouri, Forenede Stater, 63110-1010
- Washington University School Of Medicine - Center For Advanced Medicine (CAM)
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Robert Wood Johnson University Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10017
- New York University Langone Medical Center
-
Syracuse, New York, Forenede Stater, 13202
- SUNY Upstate Medical University
-
Syracuse, New York, Forenede Stater, 13210
- Associated Medical Professionals
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- The Ohio State University
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forenede Stater, 19004
- MidLantic Urology
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37209
- Urology Associates
-
-
Texas
-
Houston, Texas, Forenede Stater, 77027
- Houston Metro Urology
-
San Antonio, Texas, Forenede Stater, 78229
- Urology San Antonio Research
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- University of Washington School of Medicine
-
-
-
-
-
Bordeaux, Frankrig, 33000
- Clinique Tivoli Ducos
-
Brest, Frankrig, 29200
- ICH Hopital A. Morvan
-
Créteil, Frankrig, 94000
- Hopital Henri Mondor
-
Lille, Frankrig, 59000
- Hôpital Privé Le Bois
-
Limoges, Frankrig, 87000
- Polyclinique de Limoges - Francois Chenieux
-
Marseille, Frankrig, 13005
- Hopital de la Timone
-
Montpellier, Frankrig, 34295
- CHU Montpellier
-
Nîmes, Frankrig, 30029
- CHU Nimes
-
Paris, Frankrig, 75877
- Hopital Bichat Claude Bernard
-
Paris, Frankrig, 75015
- Hopital Europeen Georges-Pompidou
-
Pierre-Bénite, Frankrig, 69495
- Hospices Civils de Lyon HCL
-
Quint-Fonsegrives, Frankrig, 31130
- Clinical La Croix Du Sud - Ramsay Santé
-
Toulon, Frankrig, 83041
- HIA se Sainte-Anne - Toulon
-
Toulouse, Frankrig, 31076
- Clinique Pasteur
-
-
-
-
-
Almelo, Holland, 7600
- Ziekenhuisgroep Twente
-
Den Ham, Holland, 2545 AA
- Haga ziekenhuis
-
Nijmegen, Holland, 6532SZ
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, Holland, 6525 GA
- Radboud Umcn
-
-
-
-
-
Haifa, Israel, 3109601
- Rambam Health Care Campus
-
Haifa, Israel, 3436212
- Carmel Medical Center
-
Petah Tikva, Israel, 49372
- Rabin Medical Center - Hasharon Hospital
-
Ramat Gan, Israel, 52621
- The Chaim Sheba Medical Center
-
Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center
-
Yeruham, Israel, 91120
- Hadassah Medical Center
-
-
-
-
-
Avellino, Italien, 83100
- Ospedale San Giuseppe Moscati di Avellino
-
Carpi, Italien, 41012
- Ospedale Civile Ramazzini
-
Genova, Italien, 16100
- SPDC Villa Scassi
-
Milan, Italien, 20141
- Istituto Europeo di Oncologia
-
Milan, Italien, 20132
- IRCCS Ospedale San Raffaele
-
Milan, Italien, 20133
- Istituto Dei Tumori Di Milano
-
Naples, Italien, 80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Pisa, Italien, 56126
- Azienda Ospedaliero Universitaria Pisana
-
Pozzuoli, Italien, 80078
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Romagnano, Italien, 00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italien, 20089
- IRCCS Istituto Clinico Humanitas
-
Torino, Italien, 10126
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Barcelona, Spanien, 08041
- Fund. Puigvert
-
Granada, Spanien, 18016
- Hosp. Univ. San Cecilio
-
La Coruña (A Coruña), Spanien, 15006
- Hosp Univ A Coruna
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28027
- Clinica Univ. de Navarra
-
Málaga, Spanien, 29010
- Hosp Virgen de La Victoria
-
Santander, Spanien, 39002
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
-
Busan, Sydkorea, 612-030
- Inje University Haeundae Paik Hospital
-
Daegu, Sydkorea, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, Sydkorea, 42601
- Keimyung University Dongsan Hospital
-
Ganggu, Sydkorea, 06351
- Samsung Medical Center
-
Goyang, Sydkorea, 10408
- National Cancer Center
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Seoul, Sydkorea, 03722
- Severance Hospital
-
Seoul, Sydkorea, 02841
- Korea University Anam Hospital
-
Seoul, Sydkorea, 06273
- Gangnam Severance Hospital
-
Seoul, Sydkorea, 06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
Yangsan, Sydkorea, 50612
- Pusan National University Yangsan Hospital
-
-
-
-
-
Berlin, Tyskland, 10967
- Vivantes Klinikum Am Urban
-
Braunschweig, Tyskland, 38118
- Staedtisches Klinikum Braunschweig
-
Frankfurt am Main, Tyskland, 60431
- Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus
-
Halle, Tyskland, 06120
- Universitaetsklinikum Halle Saale
-
Herne, Tyskland, 44625
- Marien hospital Herne
-
Münsterhausen, Tyskland, 48149
- Universitatsklinikum Munster
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically proven, cT2-T4a N0, M0 infiltrating urothelial carcinoma of the bladder. Initial diagnosis must have been within 120 days of randomization date. Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial predominance. However, the presence of small cell or neuroendocrine variants will make a participant ineligible
- Participants with no residual tumor, or intravesical tumor size of less than or equal to (<=)3 centimeter (cm) following transurethral resection of bladder tumor (TURBT) are eligible; debulking TURBT for any residual disease is encouraged but not mandated. Participants with persistent tumors greater than (>)3 cm at screening must undergo a second debulking, re-staging TURBT. Participants will be ineligible if any individual tumor is >3 cm after debulking TURBT
- Deemed eligible for and willing to undergo RC by the operating urologist
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
- Thyroid function tests within normal range or stable on hormone supplementation per investigator assessment. Investigators may consult an endocrinologist for participant eligibility assessment in the case of equivocal or marginal tests results
- All adverse events associated with any prior surgery must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to randomization
Exclusion Criteria:
- Must not have received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment
- Participants must not have evidence of cT4b, or N1-3, or M1 disease based on central radiology staging (chest, abdomen, and pelvis must be performed using computed tomography [CT] or magnetic resonance imaging [MRI]) within 42 days prior to randomization
- Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200
- Prior systemic chemotherapy for urothelial cell carcinoma of the bladder at any time
- Currently participating or has participated in a study of an investigational agent and received study therapy or investigational device within 4 weeks prior to enrollment
- Participants with evidence of bladder perforation during diagnostic cystoscopy. Participant is eligible if perforation has resolved prior to dosing
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1: TAR-200 + Cetrelimab
Participants will receive TAR-200 in combination with cetrelimab. |
Cetrelimab will be administered.
Andre navne:
TAR-200 will be administered.
Andre navne:
|
|
Eksperimentel: Cohort 2: Cetrelimab
Participants will receive cetrelimab. |
Cetrelimab will be administered.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pathologic Complete Response (pCR) Rate
Tidsramme: At Week 12
|
pCR was defined as percentage of participants who achieved complete pathologic response. Complete pathologic response is defined as ypT0N0 (no evidence of disease) as assessed by pathologic evaluation on radical cystectomy (RC) specimen. pCR was determined by central pathologic review. |
At Week 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med behandlingsrelaterede bivirkninger ifølge Common Terminology Criteria for Adverse Event (CTCAE) version 5-graderinger
Tidsramme: Cyklusdag 1 op til uge 124
|
Cyklusdag 1 op til uge 124
|
|
Antal deltagere med værste laboratorieværdi efter baseline baseret på Common Terminology Criteria for Adverse Events (CTCAE)
Tidsramme: Cyklus dag 1 op til uge 124
|
Cyklus dag 1 op til uge 124
|
|
Recurrencefri Overlevelse (RFS)
Tidsramme: Cyklusdag 1 op til uge 124
|
Cyklusdag 1 op til uge 124
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationer og nyttige links
Generelle publikationer
- Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Powles T, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Hasan M, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. Lancet Oncol. 2025 Oct;26(10):1312-1322. doi: 10.1016/S1470-2045(25)00358-4. Epub 2025 Aug 27.
- Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Gong C, Hasan M, Urtishak K, Battaglia S, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. J Clin Oncol. 2026 Mar;44(7):586-597. doi: 10.1200/JCO-25-02382. Epub 2025 Dec 3.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CR109044
- 2020-005565-13 (EudraCT nummer)
- 17000139BLC2002 (Anden identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .